Comment: cost-effectiveness of macrolides in lower respiratory tract infections.
Renz
C L
CL
Ashraf
T
T
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D017963:Azithromycin / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D011014:Pneumonia / Q000188:drug therapy / Q000191:economics; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000191:economics*
D000900:Anti-Bacterial Agents; D017963:Azithromycin